Genentech Inc:企業の戦略的SWOT分析

【英語タイトル】Genentech Inc - Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(SWOT20MY2889)・商品コード:SWOT20MY2889
・発行会社(調査会社):GlobalData
・発行日:2020年4月
・ページ数:41
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Genentech Inc – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that discovers, develops, manufactures and commercializes medicines to address serious medical needs. It offers drugs in various therapeutic areas including oncology, immunology, ophthalmology, metabolism, neurology and infectious disease, among others. Its pipeline products include Emicizumab (RG6013, ACE910), a bispecific monoclonal antibody used to replace the function of protein in the blood clotting process; and Entrectinib (RXDX-101, RG6268), a CNS-active tyrosine-kinase inhibitor intended for the treatment of non-small cell lung cancer; among others. The company has partnership with BioLineRx, Charles River Laboratories International and Amunix, among others. Genentech is headquartered in South San Francisco, California, the US.

Genentech Inc Key Recent Developments

Mar 04,2020: Pulmonary Fibrosis Foundation launches industry consortium to identify biomarkers in Pulmonary Fibrosis
Feb 28,2020: FinnGen grows to one of the largest private-public studies in the world
Feb 26,2020: Bicycle Therapeutics, Genentech sign $1.7bn cancer therapies deal
Feb 21,2020: Leaders from 24 companies in the US Pharmaceutical Supply Chain collaborate to submit the MediLedger DSCSA Pilot Project Final Report to the FDA, proposing blockchain for an interoperable track and trace system for US prescription drugs
Feb 11,2020: Lilly and Genentech announce two failures in Alzheimer’s disease prevention study

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Genentech Inc – Key Facts
Genentech Inc – Key Employees
Genentech Inc – Key Employee Biographies
Genentech Inc – Major Products and Services
Genentech Inc – History
Genentech Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Genentech Inc – Business Description
Genentech Inc – SWOT Analysis
SWOT Analysis – Overview
Genentech Inc – Strengths
Genentech Inc – Weaknesses
Genentech Inc – Opportunities
Genentech Inc – Threats
Genentech Inc – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Genentech Inc, Recent Deals Summary
Section 4 – Company’s Recent Developments
Mar 04, 2020: Pulmonary Fibrosis Foundation launches industry consortium to identify biomarkers in Pulmonary Fibrosis
Feb 28, 2020: FinnGen grows to one of the largest private-public studies in the world
Feb 26, 2020: Bicycle Therapeutics, Genentech sign $1.7bn cancer therapies deal
Feb 21, 2020: Leaders from 24 companies in the US Pharmaceutical Supply Chain collaborate to submit the MediLedger DSCSA Pilot Project Final Report to the FDA, proposing blockchain for an interoperable track and trace system for US prescription drugs
Feb 11, 2020: Lilly and Genentech announce two failures in Alzheimer’s disease prevention study
Nov 06, 2019: Genentech, makers of new Flu treatment, Xofluza (baloxavir marboxil), announces partnership with virtual health platform, Plushcare
Oct 09, 2019: ICER finds lack of evidence to support blockbuster drug price hikes
Oct 09, 2019: Sosei Heptares to receive US$3 Million Payment from Genentech on nomination of a new GPCR Disease Target
Sep 18, 2019: SU2C to support clinical trials in breast and prostate cancers
Sep 06, 2019: JHL reaches settlement agreement with Roche/Genentech
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Genentech Inc, Key Facts
Genentech Inc, Key Employees
Genentech Inc, Key Employee Biographies
Genentech Inc, Major Products and Services
Genentech Inc, History
Genentech Inc, Other Locations
Genentech Inc, Key Competitors
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Genentech Inc, Recent Deals Summary

List of Figures
Genentech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Genentech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★調査レポート[Genentech Inc:企業の戦略的SWOT分析] (コード:SWOT20MY2889)販売に関する免責事項を必ずご確認ください。
★調査レポート[Genentech Inc:企業の戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆